ArticleGastroenterology2026
Targeting APE1-Redox Function Reverses SOX9-mediated Chemoresistance in Esophageal Adenocarcinoma.
Article in Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LINC01446/miR-338-3p/APEX1 Axis Promotes Ferroptosis Defense and Progression in Esophageal Squamous Cell Carcinoma.Cancers · 2026Article
- APE1/Ref-1: multifunctional biology, selective inhibition, and the path to clinical translation.Expert opinion on therapeutic targets · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
BACKGROUND &
aimsGastroesophageal reflux disease is the leading risk factor for esophageal adenocarcinoma (EAC), a malignancy that exhibits marked resistance to chemotherapy and results in poor clinical outcomes. This study aims to define and overcome the mechanisms underlying chemoresistance in EAC to enable the development of novel therapeutic strategies.
methodsThe study included analysis of RNA sequencing and public datasets. Experimental models consisted of 3-dimensional organotypic cultures, tumorospheres, patient-derived organoids, and de-identified tissue microarrays. In vivo experiments utilized the pL2-IL1β, Krt7CreER;R26rtTA;otet-CDX2, and patient-derived xenograft mouse models.
resultsRNA sequencing revealed a significant enrichment of the SRY-Box Transcription Factor 9 (SOX9) molecular signature in patients with EAC. We identified an apurinic/apyrimidinic endonuclease (APE1)-dependent mechanism that activates SOX9 signaling on exposure to acidic bile salts, mimicking reflux conditions. Genetic knockdown or pharmacological inhibition of APE1's redox activity suppressed SOX9 activation under both reflux-mimicking conditions and oxaliplatin treatment. The redox function of APE1 was required to stabilize the SOX9 protein. Immunostaining demonstrated co-overexpression of APE1 and SOX9 in mouse and human EAC lesions, accompanied by Aldehyde Dehydrogenase 1 Family Member A1 expression, a SOX9 transcriptional target implicated in chemotherapeutic resistance. Clinically, patients with high SOX9 signature expression had significantly worse relapse-free survival. Moreover, in vivo treatment with the APE1-redox-specific inhibitor APX2009 enhanced the response of patient-derived xenograft tumors to oxaliplatin by downregulating SOX9.
conclusionsActivation of SOX9 through the APE1-redox function is a key driver of EAC chemoresistance. Targeting APE1's redox activity offers a promising therapeutic strategy to overcome resistance by inhibiting the otherwise "undruggable" SOX9 transcription network.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.